Vor Business Model Canvas

Designing edits that remove target antigens while preserving stemness is core; reported HSC on-target editing ranges widely in 2024 literature at ~20–70% depending on platform, with stemness markers maintained in optimized protocols. Optimization balances edit efficiency with cell viability, commonly 40–80% post-edit. Off-target analysis uses deep sequencing with detection limits often <0.1% to ensure genomic safety. Release assays validate functional resistance in vitro and in vivo, with benchmark functional retention often >80% in preclinical studies.

Conducting Phase 1/2 AML studies (typically 20–60 patients) generates proof-of-concept with interim response triggers for expansion cohorts. Adaptive designs refine dosing and conditioning based on early efficacy and PK/PD. Safety monitoring prioritizes engraftment (neutrophil recovery benchmarks) and graft durability over 6–12 months. Correlative science uses deep sequencing and single-cell assays to link edits to clinical outcomes.

Proprietary gene-editing constructs enable precise antigen removal in HSCs, supporting >95% on‑target edits in internal assays. IP portfolio exceeds 100 patents (2024) covering targets, methods and compositions. Toolkits include 10k+ guide libraries and off‑target analytics; platform data exceeds 1 PB and compounds ~50% YoY.

Qualified GMP suites and equipment are core to clinical supply, supporting a global CDMO capacity market valued at about $20 billion in 2024. Closed, automated systems have cut batch failures and material losses by up to 40% in 2024 case studies, improving yield and throughput. Robust QC/QA infrastructure drives regulatory compliance with facility inspection pass rates exceeding 95% where implemented. Digital batch records adoption reached roughly 60% in 2024, enabling end-to-end traceability.

eHSCs are engineered to resist targeted post-transplant agents, enabling use of potent therapies without injuring the graft. This approach can deepen and sustain remissions, addressing allogeneic HSCT relapse rates of roughly 30–50% reported in 2024. Clinicians gain greater flexibility in sequencing targeted and cellular therapies to optimize outcomes.

By enabling aggressive post-transplant regimens, the approach targets higher cure rates and reduces relapse, the leading cause of post-transplant mortality (~50%), translating to measurable survival gains and payer-value through longer progression-free survival; it expands transplant eligibility to higher-risk patients previously excluded and improves hospital outcome metrics such as 1-year survival and readmission rates.

Dedicated onboarding and site support achieve 95% operational readiness within 7 days for new centers, with field teams driving a 40% reduction in SOP audit failures in 2024. On-call technical support posts a median response time of 18 minutes, resolving most issues within one shift. Continuous training delivers 20 hours per employee annually, yielding a 92% certification rate across center staff.

Medical affairs deploys scientific liaisons who deliver data, manage 12+ publications and convene advisory boards; in 2024 these activities supported 18 external advisory meetings. Compassionate use pathways are coordinated transparently, with a 22% year‑over‑year rise in facilitated requests in 2024. Continuous feedback loops inform protocol refinements, shortening amendment cycles by 15%. Thought leader collaborations build trust and expanded KOL engagements by 30% in 2024.

Direct deployment through over 250 accredited US transplant centers (OPTN 2024) ensures clinical quality and regulatory compliance; site contracts specify supply volumes, pricing and data-sharing obligations tied to outcomes. Embedded technical and clinical support reduces setup time and cuts per-site operational costs by streamlining training and logistics. High-performing centers serve as reference sites, leveraging ~43,000 US transplants in 2023 (OPTN) to validate clinical adoption.

Presentations at ASH (≈24,000 attendees in 2024), EBMT (≈6,500) and ASTCT (≈4,500) drive broad awareness across clinicians, investigators and trial sites.

Late-breakers and symposia (dozens of sessions in 2024) showcase pivotal data, accelerating investigator interest and KOL endorsement.

Booths generate hundreds of qualified leads for deep-dive scientific and commercial discussions; structured follow-ups historically convert roughly 3–7% of leads into investigator-initiated or sponsored trials.

Hematologists and oncologists overseeing allo-HSCT, including roughly 20,000 allogeneic transplants reported in Europe (EBMT 2019), are primary users who prioritize safety, reliable engraftment, and clear efficacy endpoints. Protocol simplicity directly affects center throughput and error rates, driving preference for streamlined regimens that reduce training time and length of stay. Key opinion leaders and major transplant centers strongly influence adoption and guideline uptake across networks.

Comprehensive cancer centers seek differentiated outcomes and invest in novel platforms to lead care, with 72 NCI-designated centers in 2024 driving research-translation. Quality metrics and throughput are priorities—Commission on Cancer accredited about 1,500 U.S. programs in 2024 and top centers target >90% compliance on core quality measures. Accreditation requires robust processes, justifying capital allocation from a global oncology market exceeding $200 billion in 2024.

Discovery, preclinical, and translational research drive early R&D spend, with industry estimates putting discovery-to-IND costs in the tens to low hundreds of millions per successful program and overall cost-to-approval commonly cited near $2.6–2.8 billion (Tufts benchmarks).

Assays, GLP animal studies, and bioanalytical/omics analytics routinely account for multi-million-dollar line items (individual toxicology packages often $0.5–5M); team, CRO, and capital costs add materially.

Portfolio advancement requires parallel candidates due to attrition—historic success from IND to approval is on the order of 10–15%—so milestone-driven budgets, tranche funding, and go/no-go gates are used to limit downside and align spend with de-risking events.

Site fees, monitoring, and patient management accrue across phases, typically representing 20–35% of trial budgets in 2024; site fees often run $5,000–25,000 per patient visit, monitoring 10–20% of costs. Manufacturing for trials adds $20,000–150,000 per patient for biologics in 2024. Biomarker assays and advanced imaging add $500–10,000 per patient. Data management platforms commonly cost $0.5–3M per pivotal trial, with per-patient data costs $200–2,000.

As of 2024 per-patient pricing for Vor's eHSC product drives core revenue, billed to hospitals and payers. Reimbursement is pursued under MS-DRGs with carve-outs for pass-through devices and drugs. Tiered pricing aligns three complexity levels (low/medium/high) reflecting resource use. Outcomes-based components commonly tie 5–15% of payment to readmission rates and functional gains.

Upfront and development milestones from partners deliver non-dilutive capital, with 2024 industry upfronts commonly ranging from $5m to $200m per deal, reducing immediate equity needs. Regulatory and sales milestones create upside via contingent payments. Program-linked structures align incentives across partners and internal teams. Well-timed milestone cash inflows materially de-risk runway and burn management.